Selecting Therapies for Cancer Patients: Past, Present, and Future Clifford Reid, PhD We are in the middle of a revolution in DNA sequencing, which has ushered in the era of precision medicine in cancer. Unfortunately, the impact of precision medicine has been quite limited, reaching only about 15% of cancer patients, and benefitting only about...Read More
An Interview with Kristin Bedard PhD, Chief Scientific Officer Kineta Immuno-Oncology. KINETA, INC. – Innovation in Cancer Care, New Drugs in High Need Areas (PART 2). Part 2 In two previous articles, our readers were introduced to the Kineta, Inc. CEO Shawn Iadonato and Kristin Bedard PhD, the Chief Scientific Officer at the company. In...Read More
Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.